- Home
- DCTH vs EIC Comparison
DCTH vs EIC Comparison
Compare DCTH & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- EIC
- Stock Information
- Founded
- DCTH 1988
- EIC N/A
- Country
- DCTH United States
- EIC United States
- Employees
- DCTH N/A
- EIC N/A
- Industry
- DCTH Medical/Dental Instruments
- EIC Finance/Investors Services
- Sector
- DCTH Health Care
- EIC Finance
- Exchange
- DCTH Nasdaq
- EIC Nasdaq
- Market Cap
- DCTH 394.9M
- EIC 343.8M
- IPO Year
- DCTH N/A
- EIC 2019
- Fundamental
- Price
- DCTH $10.96
- EIC $12.65
- Analyst Decision
- DCTH Strong Buy
- EIC Strong Buy
- Analyst Count
- DCTH 4
- EIC 1
- Target Price
- DCTH $24.00
- EIC $17.50
- AVG Volume (30 Days)
- DCTH 710.7K
- EIC 354.9K
- Earning Date
- DCTH 08-06-2025
- EIC 08-12-2025
- Dividend Yield
- DCTH N/A
- EIC 18.88%
- EPS Growth
- DCTH N/A
- EIC N/A
- EPS
- DCTH N/A
- EIC 0.55
- Revenue
- DCTH $53,850,000.00
- EIC $51,224,692.00
- Revenue This Year
- DCTH $162.10
- EIC $37.84
- Revenue Next Year
- DCTH $32.97
- EIC $23.33
- P/E Ratio
- DCTH N/A
- EIC $23.04
- Revenue Growth
- DCTH 1068.87
- EIC 68.61
- 52 Week Low
- DCTH $7.17
- EIC $12.46
- 52 Week High
- DCTH $18.23
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- DCTH 42.66
- EIC 36.85
- Support Level
- DCTH $10.44
- EIC $12.63
- Resistance Level
- DCTH $11.67
- EIC $13.15
- Average True Range (ATR)
- DCTH 0.46
- EIC 0.26
- MACD
- DCTH 0.11
- EIC -0.05
- Stochastic Oscillator
- DCTH 68.03
- EIC 23.14
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.